NervGen Pharma Stock | Analysis for April 2026, Price & Rating

NervGen Pharma

NasdaqCM:NGEN

C$ 3,92

C$-0,01 (-0,25%)

3,92 C$

C$-0,01 (-0,25%)

End-of-day quote: 04/24/2026

NervGen Pharma Stock Value

The analyst rating for NasdaqCM:NGEN is currently Outperform.

Outperform

NervGen Pharma Company Info

EPS Growth 3Y

-11,74%

Market Cap

C$0,32 B

Long-Term Debt

C$0,00 B

Short Interest

5,73%

Quarterly earnings

04/02/2026

Dividend

C$0,00

Dividend Yield

0,00%

Founded

2017

Industry

Health Care

Country

Canada

ISIN Number

CA64082X2032

Website

http://www.nervgen.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

C$9,37

139.03%

Last Update: 04/24/2026

Analysts: 6

Highest Price Target C$24,63

Average Price Target C$9,37

Lowest Price Target C$6,00

In the last five quarters, NervGen Pharma’s Price Target has risen from C$5,00 to C$5,00 - a 0,00% increase. Three analysts predict that NervGen Pharma’s share price will increase in the coming year, reaching C$9,37. This would represent an increase of 139,03%.

Top growth stocks in the health care sector (5Y.)

What does NervGen Pharma do?

NervGen Pharma Corp. engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company primarily operates in the biotechnology sector, dedicated to advancing the healing process of peripheral nerve injuries, neurodegenerative diseases, and associated dysfunctions. Business Segments The company has a singular reportable operating segment that is the research and development of pharmaceutical drugs. This...

Business Segments

The company has a singular reportable operating segment that is the research and development of pharmaceutical drugs. This distinct focus allows the company to maintain dedicated resources towards developing advanced treatments. The company understands that research and development (R&D) is a critical area for driving innovation and achieving its long-term goals. To remain at the forefront of this industry, it outsources a considerable portion of its R&D activities to contract service providers specializing in preclinical and clinical trials.

The company’s R&D efforts center on developing drugs that are expected to restore nerve function in patients suffering from various conditions. The company’s key scientific innovations push toward functional recovery with a focus on neurological health.

Business Strategy

The company’s business strategy focuses on the development of innovative therapeutic solutions for nerve injury and related conditions. The company’s long-term vision encompasses creating effective pharmaceutical products and ensuring that these products meet rigorous standards for safety and efficacy. The company recognizes the challenges inherent in bringing a drug from conception through clinical development to market approval and aims to navigate these with a well-defined plan.

The business strategy is characterized by thorough research and an empirical approach to drug development, with careful attention to market needs and emerging scientific insights. By adopting a clear focus on its core competencies, the company prioritizes its research trajectory based on credible scientific evidence and input from industry experts. The company actively seeks collaborations, partnerships, and funding opportunities to bolster its R&D initiatives and operational capabilities.

Through a commitment to innovation, the company endeavors to enhance its existing drug portfolio and to expand its research footprint in avenues that explore novel treatments for nerve regeneration.

Products and Services

The company specializes in the development of innovative pharmaceutical products aims at treating nerve injuries and neurodegenerative diseases. The company's pioneering research focuses on restoring nerve function and promoting healing. The company’s core product candidates are designed to address various forms of nerve damage that affect millions of individuals, enhancing the quality of life for patients.

The company’s primary product candidate is a proprietary compound that seeks to interact with critical biological pathways involved in nerve regeneration. Through a combination of scientific rigor and cutting-edge technology, the company aims to create formulations that significantly improve healing rates while minimizing recovery times. This research shows promise for various indications, including spinal cord injuries, peripheral neuropathies, and surgical nerve repair.

In addition to drug development, the company acknowledges the importance of effective clinical trials and patient engagement strategies. The company seeks to create a comprehensive framework that supports clinical testing and validates therapeutic outcomes, which is a vital element of its product strategy. By leveraging partnerships with experienced clinical trial organizations, the company intends to foster robust collaborations to facilitate timely and effective drug development.

Geographical Markets Served

The company operates on a global scale, with its assets and operations spanning multiple geographies, particularly focusing on the U.S., Canada, and Australia.

Customers

The company services a broad spectrum of stakeholders in the healthcare field, from healthcare providers to patients and potentially pharmaceutical partners. The company’s focus lies in delivering solutions tailored to individuals experiencing nerve injuries and conditions, alongside collaborations with hospitals, research institutions, and clinical trial centers.

The customer base is primarily categorized into patients requiring innovative therapies, healthcare professionals seeking reliable treatment options, and institutional partners engages in clinical research and drug development.

Sales and Marketing

The company adopts a strategic approach to sales and marketing that focuses on establishing an influential presence within the biotechnology sector. The company emphasizes direct engagement with healthcare professionals and institutions to create awareness of its innovative therapies targeting nerve injury recovery.

Marketing efforts are designed to communicate the unique benefits of its product candidates while providing in-depth insights into the science behind the treatments. The company aims to build strategic collaborations with healthcare providers to foster educational programs that inform practitioners about the latest developments in nerve repair therapies.

The company also utilizes digital marketing channels to enhance its outreach and connect with a broader audience, leveraging social media platforms to disseminate information about its research initiatives and product pipeline. Furthermore, participation in conferences and scientific symposiums allows the company to showcase its advancements and strengthen relationships within the healthcare community.

Government Regulations

The company operates within a highly regulated sector, subject to stringent government regulations and compliance requirements that pertain to the research, development, and commercialization of pharmaceutical products. Navigating these regulations involves rigorous adherence to standards set forth by various regulatory agencies, including Health Canada, the U.S. Food and Drug Administration (FDA), and the Therapeutic Goods Administration (TGA) in Australia.

The company remains committed to maintaining compliance with good manufacturing practices (GMP) and ensuring that all research and development activities align with ethical guidelines.

History

NervGen Pharma Corp. was incorporated in 2017.

NervGen Pharma Questions and Answers

Which sectors generate sales and which are the top 3 markets?

I'm sorry, but I do not have specific revenue data for NervGen Pharma Corp. for the year 2026. However, I can provide general information about the company and its industry focus. **Industry Focus:** Biotechnology, Neuroscience NervGen Pharma Corp. is a biopharmaceutical company that speciali...

At which locations are the company’s products manufactured?

**Production Sites:** No specific production sites known (as of 2023) NervGen Pharma Corp. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of nerve damage. Currently, no specific production sites of the company are publicly known. Typically, such co...

What strategy does NervGen Pharma pursue for future growth?

**Focus on Clinical Trials:** Phase 2 (2025) **Partnerships and Collaborations:** Several strategic alliances (2024) **Pipeline Expansion:** New therapeutic approaches (2025) NervGen Pharma Corp. focuses on the development of innovative therapies for the treatment of nerve damage. A key element o...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific information on the commodities or materials that NervGen Pharma Corp. imports, nor from which countries they originate. NervGen Pharma Corp. is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of nerve damage. C...

How strong is the company’s competitive advantage?

**Competitive Advantage:** Moderate to strong (estimated 2026) NervGen Pharma Corp. specializes in the development of innovative therapies for the treatment of nerve damage. A key competitive advantage of the company lies in its proprietary technology platform based on the modulation of protein tyr...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 38% (2026, estimated) **Insider Buys/Sells:** No significant changes in the last quarter (2026, estimated) The institutional investor share of NervGen Pharma Corp. is estimated to be 38%. This indicates a moderate interest from institutional investors in the comp...

What percentage market share does NervGen Pharma have?

**Market share of NervGen Pharma Corp.:** Estimate: 2-3% (2026) **Top competitors and their market share:** 1. Biogen Inc. - Market share: 15% 2. Roche Holding AG - Market share: 12% 3. Novartis AG - Market share: 10% 4. Merck & Co., Inc. - Market share: 8% 5. Johnson & Johnson - Market sha...

Is NervGen Pharma stock currently a good investment?

**Revenue Growth:** 18% (2025) **Research and Development Expenses:** 35% of revenue (2025) **Pipeline Progress:** Two drugs in Phase III study (2026) NervGen Pharma Corp. shows strong revenue growth of 18% in 2025, indicating successful progress in their product development and increased demand fo...

Does NervGen Pharma pay a dividend – and how reliable is the payout?

**Dividend:** No payout (as of 2023) NervGen Pharma Corp. is a biopharmaceutical company focused on developing innovative therapies for the treatment of nerve damage. As of 2023, the company has not paid any dividends to its shareholders. Since NervGen Pharma is in a growth and development phase,...

New support ticket

Explore

NervGen Pharma Stock Value

NervGen Pharma Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does NervGen Pharma do?

NervGen Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

NervGen Pharma Stock Value

NervGen Pharma Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does NervGen Pharma do?

NervGen Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.